Long-term macrolides in diffuse interstitial lung diseases
Autor: | Francesco Bini, Alberto Pesci, Paola Faverio, Adriano Vaghi |
---|---|
Přispěvatelé: | Faverio, P, Bini, F, Vaghi, A, Pesci, A |
Jazyk: | angličtina |
Rok vydání: | 2017 |
Předmět: |
Pulmonary and Respiratory Medicine
Time Factors Treatment outcome Drug Administration Schedule 03 medical and health sciences Idiopathic pulmonary fibrosis 0302 clinical medicine Medicine Animals Humans 030212 general & internal medicine Lung Surfactant homeostasis lcsh:RC705-779 Bacteria business.industry Intracellular protein Autophagy Disease progression lcsh:Diseases of the respiratory system medicine.disease Organising pneumonia Anti-Bacterial Agents medicine.anatomical_structure Treatment Outcome 030228 respiratory system Immunology Host-Pathogen Interactions Macrolides business Lung Diseases Interstitial |
Zdroj: | European Respiratory Review, Vol 26, Iss 146 (2017) |
ISSN: | 1600-0617 0905-9180 |
Popis: | In the present review we provide currently available evidence for the use of macrolides in the treatment of diffuse interstitial lung diseases (ILDs). Up to now, research on macrolides has mainly focused on three areas. First, macrolides have shown some promising results in cellular models and case reports as antifibrotic agents, by promoting autophagy and clearance of intracellular protein aggregates and acting as regulators of surfactant homeostasis. Secondly, macrolides have an immunomodulatory effect, which has been applied in some organising pneumonia cases. In particular, macrolides have been tested in association with systemic corticosteroids as steroid-sparing agents and alone as either first-line agents in mild cases or second-line agents where steroids were poorly tolerated or had failed. Thirdly, a recent area of research concerns the possible role of macrolides as modulators of lung microbiota and the host–microbiota interaction. This function has been particularly studied in idiopathic pulmonary fibrosis patients, in whom changes in microbiota have been proved to be associated with disease progression. However, the lack of high-quality studies makes the application of macrolide therapy in ILDs a field in which research should be conducted on a large scale. |
Databáze: | OpenAIRE |
Externí odkaz: |